Company profile
MOONLAKE IMMUNOTHERAPEUTICS
NASDAQ:MLTXBiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| SONELOKIMAB | phase3 | — | 10 | active |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (10)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06411899 | phase3 | completed | 2024-05-15 | 2025-09-02 | MoonLake Immunotherapeutics AG | A Study to Evaluate the Efficacy and Safety of Subcutaneous Sonelokimab Compared With Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa |
| NCT07007637 | phase3 | enrolling_by_invitation | 2025-06-27 | 2028-06-13 | MoonLake Immunotherapeutics AG | A Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Subcutaneous Sonelokimab in Participants With Moderate to Severe Hidradenitis Suppurativa |
| NCT07223138 | phase3 | enrolling_by_invitation | 2025-11-13 | 2028-02-04 | MoonLake Immunotherapeutics AG | A Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Subcutaneous Sonelokimab in Participants With Psoriatic Arthritis |
| NCT06994936 | phase1 | completed | 2025-06-05 | 2025-11-01 | MoonLake Immunotherapeutics AG | An Open-label Study in Healthy Adults to Evaluate the Relative Bioequivalence of a Single-dose Administration of Sonelokimab Either by a Prefilled Syringe or an Autoinjector |
| NCT06768671 | phase3 | active_not_recruiting | 2024-12-30 | 2026-09-28 | MoonLake Immunotherapeutics AG | An Open-label, Single-arm Study to Evaluate Pharmacokinetics and Safety of Subcutaneous Sonelokimab in Adolescents With Moderate to Severe Hidradenitis Suppurativa (VELA-TEEN) |
FDA applications (0)
No records yet.